Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Express Scripts
Medtronic
Colorcon
McKesson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR PEMFEXY


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pemfexy

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02194738 ↗ Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting National Cancer Institute (NCI) N/A 2014-08-18 This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
NCT02419495 ↗ Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies Recruiting Karyopharm Therapeutics, Inc Phase 1 2015-06-26 This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Studying selinexor with different standard chemotherapy or immunotherapy regimens may help doctors learn the side effects and best dose of selinexor that can be given with different types of treatments in one study.
NCT02419495 ↗ Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies Recruiting National Cancer Institute (NCI) Phase 1 2015-06-26 This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Studying selinexor with different standard chemotherapy or immunotherapy regimens may help doctors learn the side effects and best dose of selinexor that can be given with different types of treatments in one study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pemfexy

Condition Name

Condition Name for Pemfexy
Intervention Trials
Stage IV Lung Cancer AJCC v8 9
Stage IVB Lung Cancer AJCC v8 8
Stage IIIC Lung Cancer AJCC v8 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pemfexy
Intervention Trials
Carcinoma, Non-Small-Cell Lung 18
Lung Neoplasms 16
Carcinoma 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pemfexy

Trials by Country

Trials by Country for Pemfexy
Location Trials
United States 155
Canada 6
Spain 3
Guam 2
Japan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pemfexy
Location Trials
Texas 9
Tennessee 4
Arkansas 4
Ohio 4
Colorado 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pemfexy

Clinical Trial Phase

Clinical Trial Phase for Pemfexy
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 2
Phase 2 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pemfexy
Clinical Trial Phase Trials
Not yet recruiting 9
Recruiting 8
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pemfexy

Sponsor Name

Sponsor Name for Pemfexy
Sponsor Trials
National Cancer Institute (NCI) 13
M.D. Anderson Cancer Center 5
NRG Oncology 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pemfexy
Sponsor Trials
NIH 13
Other 10
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Moodys
Mallinckrodt
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.